| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1818 | 2020 |
| Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ... The Lancet Oncology 22 (6), 790-800, 2021 | 322 | 2021 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 281 | 2021 |
| Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma AS LaCasce, RG Bociek, A Sawas, P Caimi, E Agura, J Matous, ... Blood, The Journal of the American Society of Hematology 132 (1), 40-48, 2018 | 217 | 2018 |
| Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC … K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ... The Lancet Haematology 5 (12), e609-e617, 2018 | 185 | 2018 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design KT Flaherty, R Gray, A Chen, S Li, D Patton, SR Hamilton, PM Williams, ... JNCI: Journal of the National Cancer Institute 112 (10), 1021-1029, 2020 | 163 | 2020 |
| NCCN guidelines insights: B-cell lymphomas, version 3.2019: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JS Abramson, RH Advani, NL Bartlett, PF Caimi, ... Journal of the National Comprehensive Cancer Network 17 (6), 650-661, 2019 | 163 | 2019 |
| Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma M Hamadani, J Radford, C Carlo-Stella, PF Caimi, E Reid, OA O’Connor, ... Blood, The Journal of the American Society of Hematology 137 (19), 2634-2645, 2021 | 142 | 2021 |
| Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, ... Journal of Clinical Oncology 39 (15), 1609, 2021 | 124 | 2021 |
| NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JE Chang, B Christian, JS Abramson, RH Advani, ... Journal of the National Comprehensive Cancer Network 19 (11), 1218-1230, 2021 | 110 | 2021 |
| Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies A Forero-Torres, R Ramchandren, A Yacoub, MS Wertheim, WJ Edenfield, ... Blood, The Journal of the American Society of Hematology 133 (16), 1742-1752, 2019 | 93 | 2019 |
| A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma BS Kahl, M Hamadani, J Radford, C Carlo-Stella, P Caimi, E Reid, ... Clinical Cancer Research 25 (23), 6986-6994, 2019 | 92 | 2019 |
| Gray zone lymphoma with features intermediate between classical H odgkin lymphoma and diffuse large B‐cell lymphoma: C haracteristics, outcomes, and prognostication among a … AM Evens, JA Kanakry, LH Sehn, A Kritharis, T Feldman, A Kroll, ... American journal of hematology 90 (9), 778-783, 2015 | 91 | 2015 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 87 | 2021 |
| Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ... Journal of Clinical Oncology 37 (6), 471-480, 2019 | 87 | 2019 |
| Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma AS LaCasce, G Bociek, A Sawas, PF Caimi, E Agura, J Matous, S Ansell, ... Blood 126 (23), 3982, 2015 | 81 | 2015 |
| Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma K Dunleavy, M Fanale, A LaCasce, A Noy, P Caimi, S Parekh, JW Hayslip, ... Blood, The Journal of the American Society of Hematology 124 (21), 395-395, 2014 | 76 | 2014 |
| Emerging therapeutic approaches for multipotent mesenchymal stromal cells PF Caimi, J Reese, Z Lee, HM Lazarus Current opinion in hematology 17 (6), 505-513, 2010 | 74 | 2010 |
| Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia MW Harr, PF Caimi, KS McColl, F Zhong, SN Patel, PM Barr, ... Cell Death & Differentiation 17 (9), 1381-1391, 2010 | 73 | 2010 |
Mehdi HamadaniMedical College of Wisconsin & CIBMTRVerified email at mcw.edu
